Oct 6, 2026 · 30 min
China’s biotech assets go global as Medicare pricing models shrink
Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
The episode connects cross-border drug innovation, trade-secret litigation, federal pricing policy, and optogenetics’ path from Nobel-recognized science toward clinical use.
- 1Multinational partnerships increasingly treat Chinese biotech assets as globally valuable, even when their developers remain domestically focused.
- 2Beam’s lawsuit against YolTech highlights the difficulty of proving that confidential failed research accelerated a competitor’s program.
- 3The GLOBE and GUARD pricing models have narrowed, while optogenetics shows how basic tools can reshape neurological medicine.
Don't miss
The Beam-YolTech discussion exposes why proving that stolen negative information accelerated a rival’s research can be unusually difficult.
The brief
BioCentury editors examine the surge in multinational partnerships with Chinese biotechs, arguing that the assets’ quality and originality are changing how global drugmakers source innovation.
Merck KGaA, Novo Holdings, and Novartis appear in a broader debate over licensing, co-development, and co-commercialization—and whether Chinese assets can globalize without their creators expanding overseas.
Beam’s lawsuit against YolTech turns on a difficult question: can a company prove that confidential negative information or failed research paths helped accelerate a rival’s program?
Steve Usdin explains how the Trump administration’s GLOBE and GUARD most-favored-nation models have narrowed, affecting physician-administered biologics and retail prescriptions while facing possible court intervention.
The episode closes with Nobel-recognized optogenetics, whose light-sensitive proteins and related imaging tools show how foundational neuroscience can open routes toward neurological therapies.
What was said on this episode
21 statements · 10 positive · 5 negative · 6 neutral
China biopharma deal count has already surpassed prior full-year totals.
“This year's China deal count already exceeds that of prior years, and it's only October.”
Listen at 0:01
Multinational pharma deals with China-based biotechs have increased substantially.
“There's just a huge increase.”
Listen at 4:19
China biotech deals are nine higher year-to-date than last year.
“I think we have nine more deals already this year to date than we had last year.”
Listen at 4:21
Recent China biotech deals had upfronts above $300 million and values above $2 billion.
“These were relatively big deals. They all had upfront payments of over $300 million or more with total deal values over $2 billion.”
Listen at 4:46
One recent China biotech deal exceeded $7 billion in total value.
“One of them was over $7 billion.”
Listen at 4:58
More large biotech co-development deals may produce more restrictive Treasury rules.
“that's likely to fuel a more restrictive rules when we do see Treasury putting out its rules on how it's going to incorporate biotech into coins.”
Listen at 7:40
RNA-encoded T-cell engagers represent a new therapy class.
“This is kind of a new class of therapies there.”
Listen at 9:09
Beam Therapeutics filed a trade-secret lawsuit against Yoltec.
“Beam Therapeutics filed suit on September 25 in the U.S. District Court for the District of Massachusetts.”
Listen at 11:49
A trial outcome would depend heavily on explaining complex science to jurors.
“the outcome of a trial, again, if it does go to trial, is going to hinge a lot on the two sides' ability to make very complex scientific information accessible to jurors.”
Listen at 15:24
Prime Medicine prevailed in its arbitration with Beam.
“Prime prevailed in that arbitration.”
Listen at 18:21
Globe projected savings have fallen to approximately $440 million.
“That has shriveled to about $440 million.”
Listen at 20:47
Globe will likely face a court challenge.
“I think that Globe is going to be challenged in court”
Listen at 21:11
Globe’s policy precedent matters more than its financial savings.
“The precedent really does matter more than the money here.”
Listen at 21:42
Democrats may pursue international reference pricing through the IRA and other programs.
“they're going to try to do it through the IRA, through the Medicare drug price negotiation program, and in other ways.”
Listen at 22:34
Presidential negotiation of drug prices will outlast the Globe model.
“that's a precedent that's going to outlast whatever happens with the Globe model”
Listen at 22:59
Globe and Guard are scheduled to begin January 1.
“both Globe and Guard are going to start January 1.”
Listen at 23:46
Litigation challenging Globe and Guard is quite likely.
“I think litigation is quite likely.”
Listen at 23:54
Optogenetics can control specific synaptic circuits.
“it is a way to... control, turn on or off specific synaptic circuits.”
Listen at 24:45
Optogenetics enables investigation of circuit-level mechanisms in neurological diseases.
“you can start to ask questions about, well, what goes wrong at the circuit level in certain kinds of dementias or certain kinds of psychiatric diseases”
Listen at 26:04
Optogenetics can serve as a therapeutic modality in some settings.
“there are a few places where it can be used as a therapeutic modality itself.”
Listen at 26:27
Optogenetic therapy is used mainly for eye diseases.
“And that's mostly in the eye”
Listen at 26:32
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.